Severe atopic dermatitis in adolescents represents a significant burden in quality of life and healthcare resource use, within a context of expanding systemic treatment options.
This analysis shows that abrocitinib may provide a more efficient alternative compared to dupilumab, delivering improved health outcomes alongside lower costs from the Spanish NHS perspective.
Findings support value optimisation in reimbursement and treatment positioning decisions, particularly under increasing budgetary pressure.